PDX model details
| PDX ID |
294R |
| Host Strain(and Source) |
NSG Source: Monash University |
| Host Strain Immune system Humanized |
NO |
| Host Type |
Testosterone supplemented |
| Graft Site |
Renal |
Current Generation (* indicates number of generations grown in Castrate host) |
7 |
| Average PDX Generation Time (days +/- SEM) |
188 ± 45 |
| Tumour preparation |
Tumor solid |
| Tumour Characterization Technology |
Histology, IHC, STR profiling, targeted DNA sequencing, RNAseq |
| Tumour confirmed not to be of Mouse/EBV origin |
Yes; negative for CD45 and/or positive for human CK8/18 and/or human mitochondria by IHC |
| Passage QA performed |
Routine QA every 2-3 passages |
| Associated meta data |
| PDX model availability |
Yes (fixed, frozen) |
| Governance restriction for distribution |
Available to investigators with appropriate ethics approvals, approved EOI from MURAL committee, and material transfer agreements |
| Pubmed ID |
34413304 |
| |
|
| Markers |
294R |
| AR |
Y |
| PSA |
Y |
| PSMA |
Y |
| NE |
N |
| ERG |
N |
This heatmap displays the call type of curated CNVs in the presented samples.
This heatmap displays the call type of CNVs in commonly occurred samples.
This table displays curated CNVs
|
PDX ID
|
Gene Symbol
|
CNV Log2
|
CNV Copy
|
CNV Call
|
Experiments name
|
Platform
|
Reference genome
|
| 294R |
BRAF |
0.659722 |
3.15956 |
gain
|
MURAL Prostate Cancer PDX collection |
Targeted GARVAN Panel |
hg19 |
| 294R |
BRCA2 |
-0.828353 |
1.12634 |
loss
|
MURAL Prostate Cancer PDX collection |
Targeted GARVAN Panel |
hg19 |
| 294R |
EZH2 |
0.659722 |
3.15956 |
gain
|
MURAL Prostate Cancer PDX collection |
Targeted GARVAN Panel |
hg19 |
| 294R |
FANCD2 |
-0.827292 |
1.12717 |
loss
|
MURAL Prostate Cancer PDX collection |
Targeted GARVAN Panel |
hg19 |
| 294R |
KMT2C |
0.659722 |
3.15956 |
gain
|
MURAL Prostate Cancer PDX collection |
Targeted GARVAN Panel |
hg19 |
| 294R |
PTEN |
-0.99398 |
1.00418 |
loss
|
MURAL Prostate Cancer PDX collection |
Targeted GARVAN Panel |
hg19 |
| 294R |
RB1 |
-0.765237 |
1.17671 |
loss
|
MURAL Prostate Cancer PDX collection |
Targeted GARVAN Panel |
hg19 |
| 294R |
SMAD2 |
-0.761822 |
1.1795 |
loss
|
MURAL Prostate Cancer PDX collection |
Targeted GARVAN Panel |
hg19 |
| 294R |
SUFU |
-0.99398 |
1.00418 |
loss
|
MURAL Prostate Cancer PDX collection |
Targeted GARVAN Panel |
hg19 |
Clinical Information
| Sample Number |
294R |
| Sample Site |
Prostate |
| Sample source |
Radical prostatectomy |
| Pathology Tumour Diagnosis |
Adenocarcinoma |
| Gleason Score |
9 |
| Primary Gleason Score |
5 |
| Secondary Gleason Score |
4 |
| Tertiary Gleason Score |
None |
| ISUP Grade Group |
5 |
| Tumour Grade |
PT3bN0 |
| D'Amico Risk Classification |
7 |
| Tumour Volume (in cc) |
30.2 |
| Treatment Prior to Specimen Collection |
None |
| |
|
Patient Information
| Patient Number |
294 |
| Sex |
Male |
| Diagnosis |
Prostate Cancer |
| PSA at diagnosis (ng/mL) |
5.6 |
| Consent to share data |
|
| |
|
This heatmap displays the mutations of curated sequence variants.
Download
This table displays curated sequence variants
|
PDX ID
|
Gene Symbol
|
Depth
|
ALT_FREQ
|
Consequence
|
Exon
|
GnomAD_AF
|
CADD_PHRED
|
Clinvar_clnsig
|
Platform
|
Experiments Name
|
Reference
|
Library Type
|
Instrument Type
|
| 294R |
SUFU |
248 |
0.95 |
missense_variant |
'7/12 |
0.0002356 |
23.1 |
Conflicting_interpretations_of_pathogenicity
|
Targeted GARVAN Panel |
MURAL Prostate Cancer PDX collection |
hg19 |
paired |
Illumina HiSeq 2500 |
| 294R |
BRCA2 |
336 |
0.95 |
frameshift_variant |
'11/28 |
0.0002723 |
. |
-
|
Targeted GARVAN Panel |
MURAL Prostate Cancer PDX collection |
hg19 |
paired |
Illumina HiSeq 2500 |
| 294R |
EP300 |
362 |
0.71 |
missense_variant |
'10/31 |
4.06E-06 |
23.6 |
-
|
Targeted GARVAN Panel |
MURAL Prostate Cancer PDX collection |
hg19 |
paired |
Illumina HiSeq 2500 |
| 294R |
LRP1B |
471 |
0.65 |
missense_variant |
'44/91 |
. |
29.3 |
-
|
Targeted GARVAN Panel |
MURAL Prostate Cancer PDX collection |
hg19 |
paired |
Illumina HiSeq 2500 |
| 294R |
FGF3 |
450 |
0.46 |
missense_variant |
'2/3 |
. |
27.2 |
-
|
Targeted GARVAN Panel |
MURAL Prostate Cancer PDX collection |
hg19 |
paired |
Illumina HiSeq 2500 |
| 294R |
MYC |
689 |
0.46 |
missense_variant |
'3/3 |
7.31E-05 |
24.2 |
-
|
Targeted GARVAN Panel |
MURAL Prostate Cancer PDX collection |
hg19 |
paired |
Illumina HiSeq 2500 |
| 294R |
JPH2 |
45 |
0.36 |
missense_variant |
'2/6 |
0.0006877 |
16.43 |
Conflicting_interpretations_of_pathogenicity
|
Targeted GARVAN Panel |
MURAL Prostate Cancer PDX collection |
hg19 |
paired |
Illumina HiSeq 2500 |
| 294R |
ATM |
436 |
0.32 |
missense_variant,splice_region_variant |
'57/63 |
. |
32 |
Uncertain_significance
|
Targeted GARVAN Panel |
MURAL Prostate Cancer PDX collection |
hg19 |
paired |
Illumina HiSeq 2500 |
| 294R |
UGT1A5 |
437 |
0.3 |
missense_variant |
'5/5 |
. |
26.9 |
-
|
Targeted GARVAN Panel |
MURAL Prostate Cancer PDX collection |
hg19 |
paired |
Illumina HiSeq 2500 |
| 294R |
UGT1A4 |
437 |
0.3 |
missense_variant |
'5/5 |
. |
26.9 |
-
|
Targeted GARVAN Panel |
MURAL Prostate Cancer PDX collection |
hg19 |
paired |
Illumina HiSeq 2500 |
| 294R |
UGT1A9 |
437 |
0.3 |
missense_variant |
'5/5 |
. |
26.9 |
-
|
Targeted GARVAN Panel |
MURAL Prostate Cancer PDX collection |
hg19 |
paired |
Illumina HiSeq 2500 |
| 294R |
UGT1A7 |
437 |
0.3 |
missense_variant |
'5/5 |
. |
26.9 |
-
|
Targeted GARVAN Panel |
MURAL Prostate Cancer PDX collection |
hg19 |
paired |
Illumina HiSeq 2500 |
| 294R |
UGT1A10 |
437 |
0.3 |
missense_variant |
'5/5 |
. |
26.9 |
-
|
Targeted GARVAN Panel |
MURAL Prostate Cancer PDX collection |
hg19 |
paired |
Illumina HiSeq 2500 |
No information in Drug dosing Table